Clinical Trial News and Research

RSS

Transplanted neural stem cells able to produce new myelin in children with PMD

A Phase I clinical trial led by investigators from the University of California, San Francisco and sponsored by Stem Cells Inc., showed that neural stem cells successfully engrafted into the brains of patients and appear to have produced myelin.

11 Oct 2012

Six-gene signature can predict survival in men with aggressive prostate cancer

Researchers from Mount Sinai School of Medicine have identified a six-gene signature that can be used in a test to predict survival in men with aggressive prostate cancer, according to new research published in the October issue of The Lancet Oncology.

11 Oct 2012

NewLink Genetics to launch algenpantucel-L Phase 3 study in pancreatic cancer

NewLink Genetics Corporation announces launching of an open-label, randomized, multi-institutional Phase 3 study in patients with borderline resectable or locally advanced unresectable pancreatic cancer.

10 Oct 2012

Spanish and British scientists design new blood test to identify aggressive prostate cancer

Scientists from the Spanish National Cancer Research Centre (CNIO) in Madrid, along with British colleagues from the Institute for Cancer Research (ICR) and the Royal Marsden NHS Foundation Trust, have developed a test that studies genetic patterns in blood cells to detect advanced-stage prostate cancer.

10 Oct 2012

PARP-1 plays a major role in controlling AR function in prostate cancer patients

A newly discovered function of PARP-1 could be the key to more effective therapeutics to treat advanced prostate cancer patients, a recent preclinical study published in Cancer Discovery by Jefferson's Kimmel Cancer Center researchers suggests.

10 Oct 2012

Boston Scientific initiates enrollment in Lotus Valve System clinical trial for aortic valve disease

Boston Scientific has enrolled the first patient in the REPRISE II clinical trial to evaluate the safety and performance of the Lotus Valve System in up to 120 patients with severe aortic valve disease.

10 Oct 2012

GSK, Aeras to advance clinical development of TB vaccine

Aeras announces that it has signed an agreement with GlaxoSmithKline Vaccines, S.A. (GSK) to jointly advance the clinical development of an investigational tuberculosis (TB) vaccine containing GSK's proprietary M72 antigen and AS01E adjuvant.

10 Oct 2012

Transfused blood age does not impact outcomes in premature babies

Using fresh red blood cells for premature babies who need blood transfusions does not improve outcomes over use of standard blood bank donations, show study findings published in JAMA.

9 Oct 2012

Johns Hopkins joins API’s Actimab-A Phase I/II trial in acute myeloid leukemia

Actinium Pharmaceuticals, Inc. (API), a biopharmaceutical company that develops innovative targeted payload immunotherapeutics, announced that Johns Hopkins University School of Medicine in Baltimore, MD has joined the Company's ongoing Phase I/II trial in newly diagnosed elderly patients with acute myeloid leukemia (AML).

9 Oct 2012

New data from Genzyme's AUBAGIO and LEMTRADA clinical trials to be presented at ECTRIMS

Genzyme, a Sanofi company, announced today new data from Genzyme's clinical development programs for AUBAGIO (teriflunomide) and LEMTRADATM (alemtuzumab) will be presented at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Lyon, France, October 10-13.

9 Oct 2012

ARIPI trial: Fresh blood not better for acutely ill premature babies

In a finding that runs counter to commonly held beliefs about fresh being better, a clinical trial published today by the Journal of the American Medical Association shows that acutely ill premature babies who received fresher blood did not fare better than those who received the current standard of care. There was no difference between the two approaches with respect to major organ injury, mortality and infection.

9 Oct 2012

Clinical trial to investigate safety and effectiveness of Elagolix against endometriosis

According to the Centers for Disease Control (CDC), endometriosis, a gynecological disorder in which cells from the uterus lining grow in other areas of the body, is the number one reason for a hysterectomy in women ages 18-35. Current treatment options for endometriosis are severely limited by side effects of existing medications and surgical options have more risks. A nationwide clinical trial is testing an investigational drug as a potential new option for patients with moderate to severe pain from this disease.

9 Oct 2012

Group-based behavioral weight loss treatment effective in treating obesity

A new National Institutes of Health (NIH)-funded study conducted at Baruch College and published in Obesity found that overweight and obese adults who participated in three different weight loss treatments, all involving intensive, multi-component counseling delivered in groups, lost significant weight after 48 weeks whether the treatment was led by a health professional or by someone who had previous weight loss success.

9 Oct 2012

Rainbow, Amarantus report joint venture agreement for NuroPro Parkinson's diagnostic platform

Rainbow Coral Corp. biotech subsidiary Rainbow BioSciences and Amarantus Biosciences have moved into the final stages of the terms for a deal. The pending joint venture agreement will see the two entities working together to move the Amarantus NuroPro Parkinson's diagnostic platform towards commercialization.

8 Oct 2012

Functional profiling using EVA/PCD doubles response rate and improves survival in NSCLC patients

Functional profiling using ex-vivo analysis of programmed cell death (EVA/PCD) doubles the response rate and improves time-to-progression and survival in patients with advanced lung cancer, according to a Phase II clinical trial conducted by investigators at Rational Therapeutics and the MemorialCare Todd Cancer Institute and published in the October issue of Anticancer Research.

8 Oct 2012

Rember revamped for Phase 3 testing in behavioral-variant frontotemporal dementia

Rember—the blue dye that created a stir in 2008 when Phase 2 clinical trial data claimed that it slowed decline in people with Alzheimer's disease—has now been revamped for Phase 3 testing in another disease, behavioral-variant frontotemporal dementia (bvFTD).

6 Oct 2012

Many breast cancer survivors insufficiently active after leaving supervised programs

More than 40 percent of older breast cancer survivors are insufficiently active after leaving a supervised program. But new research shows that those women who developed behavioral skills such as self-confidence and motivation during their program were far more likely to continue exercising on their own.

6 Oct 2012

Major depression goes unnoticed in pregnant women

Healthcare professionals looking after pregnant women should maintain a high level of awareness for the possibility of major depressive disorder, say US researchers who found the condition frequently goes undetected.

5 Oct 2012

Favorable preliminary results from XenoPort’s XP23829 Phase 1 trial on RRMS, psoriasis

XenoPort, Inc. announced today favorable preliminary results from a Phase 1 clinical trial in healthy adults designed to assess the pharmacokinetics (PK), safety and tolerability of single doses of four different oral formulations of XP23829, a novel fumaric acid ester compound that is a prodrug of monomethyl fumarate (MMF).

5 Oct 2012

Longer looks: The time is now for community health workers; Patients sharing in medical decisions; One doctor's plea for help

By the time Frederick Pegues Jr. was resting in bed at Temple University Hospital, the irony struck him hard. Here, he had just finished a month-long course in being a community health worker, sponsored by Temple University Hospital. He had learned how to help patients navigate a complicated health system. Yet he himself had not been able to get the help he needed.

5 Oct 2012

Clinical Trial News and Research

Transplanted neural stem cells able to produce new myelin in children with PMD

Six-gene signature can predict survival in men with aggressive prostate cancer

NewLink Genetics to launch algenpantucel-L Phase 3 study in pancreatic cancer

Spanish and British scientists design new blood test to identify aggressive prostate cancer

PARP-1 plays a major role in controlling AR function in prostate cancer patients

Boston Scientific initiates enrollment in Lotus Valve System clinical trial for aortic valve disease

GSK, Aeras to advance clinical development of TB vaccine

Transfused blood age does not impact outcomes in premature babies

Johns Hopkins joins API’s Actimab-A Phase I/II trial in acute myeloid leukemia

New data from Genzyme's AUBAGIO and LEMTRADA clinical trials to be presented at ECTRIMS

ARIPI trial: Fresh blood not better for acutely ill premature babies

Clinical trial to investigate safety and effectiveness of Elagolix against endometriosis

Group-based behavioral weight loss treatment effective in treating obesity

Rainbow, Amarantus report joint venture agreement for NuroPro Parkinson's diagnostic platform

Functional profiling using EVA/PCD doubles response rate and improves survival in NSCLC patients

Rember revamped for Phase 3 testing in behavioral-variant frontotemporal dementia

Many breast cancer survivors insufficiently active after leaving supervised programs

Major depression goes unnoticed in pregnant women

Favorable preliminary results from XenoPort’s XP23829 Phase 1 trial on RRMS, psoriasis

Longer looks: The time is now for community health workers; Patients sharing in medical decisions; One doctor's plea for help

Event guide: 15th World Clinical Biomarkers & CDx Europe eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer